Va. Federal Judge Finds 2023 Mifepristone REMS Decision Arbitrary, Remands To FDA
CHARLOTTESVILLE, Va. — A Virginia federal judge held that the U.S. Food and Drug Administration acted arbitrarily and capriciously when it instituted a 2023 risk evaluation and mitigation strategy (REMS) decision...To view the full article, register now.
Already a subscriber? Click here to view full article